Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status

Pathway Genomics today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.

Pathway Genomics Launches BRCA1/2 Genetic Test with One for One Program

Pathway Genomics today announced it has launched BRCATrueTM, a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

To enhance the accessibility of this important genetic test, Pathway Genomics has developed the BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.